![Alan Parker PhD, FLSW](https://profiles-cardiff.imgix.net/attachments/2538?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Alan Parker
(e/fe)
PhD, FLSW
Athro Virotherapies Cyfieithu. Pennaeth Adran Canser Solid, Is-adran Canser a Geneteg
- Sylwebydd y cyfryngau
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Mae gen i ddiddordeb hir mewn firoleg a sut y gellir cymhwyso hyn at therapïau canser gan ddefnyddio fectorau "oncolytig" seiliedig ar adenoviral ("virotherapy"), sy'n deillio'n ôl i'm PhD (a ddyfarnwyd yn 2003 gan Brifysgol Birmingham.)
Cyn symud i Gaerdydd, roeddwn yn astudio fectorau adenoviral ar gyfer cymwysiadau trosiadol mewn clefyd cardiofasgwlaidd, lle roedd fy ymchwil wedi amlygu rhyngweithiadau allweddol rhwng firysau â ffactorau ceulo gwaed cynnal (yn fwyaf arbennig Ffactor X) sy'n pennu trobwynt a gwenwyndra fectorau firaol a weinyddir yn fewnwythiennol. Symudais i Brifysgol Caerdydd yn 2013, wedi'i yrru gan uchelgais hirdymor i arwain tîm sy'n arwain y byd yn datblygu "virotherapies" ar gyfer trin canser. Yn syth ar ôl fy recriwtio, dechreuais ddatblygu tîm, sydd bellach yn rhifo bron i 20. Cefais fy nyrchafu i Uwch-ddarlithydd yn 2014, i Ddarllenydd yn 2018, ac i Gadair Bersonol yn 2020.
Mae ymchwil yn fy ngrŵp yn canolbwyntio ar sawl agwedd ar adenoviroleg, gyda'r nod cyffredinol o ddatblygu firotherapïau mwy dethol ac effeithiol ar gyfer cymwysiadau trosiadol mewn canser, sef:
- Diffinio ac atal dos yn enetig sy'n cyfyngu ar ryngweithio rhwng celloedd firws a gwesteiwr, proteinau a derbynyddion.
- Datblygu technolegau targedu sy'n galluogi fectorau adenofirysol yn effeithlon i heintio celloedd canseraidd, gan adael celloedd "normal" heb eu heintio.
- Datblygu seroteipiau newydd o fectorau Adenoviral gyda trofannau newydd a chyffrous ar gyfer cymwysiadau trosiadol.
Rwy'n llysgennad STEMNet (http://networking.stemnet.org.uk/user/30519 cofrestredig), ac yn angerddol am yr angen i ymgysylltu â'r gymuned leyg i gyfleu gwyddoniaeth. Rwy'n chwarae rhan flaenllaw mewn ystod o weithgareddau ymgysylltu, gan gynnwys cyflwyno yn y diwrnod ymgysylltu cyhoeddus BSGCT blynyddol cyn y gynhadledd flynyddol, a hefyd mewn digwyddiadau "mewnol" ym Mhrifysgol Caerdydd, lle rwyf wedi ymddangos mewn sawl erthygl blog (e.e. gweler https://www.bsgct.org/virotherapy-showcased-at-cardiff-cancer-open-day/ a https://www.youtube.com/watch?v=3iZquZ4K5E4 ). Yn fy rôl fel llysgennad STEM, rydw i'n mynychu fy ysgol leol yn rheolaidd i ennyn diddordeb y myfyrwyr mewn therapi genynnau a fy rôl fel gwyddonydd, a helpu gyda ffug gyfweliadau. Mae fy ngweithgareddau ymwneud ac ymgysylltu wedi ymddangos mewn Astudiaeth Achos Ysgol Meddygaeth (gweler https://www.cardiff.ac.uk/medicine/about-us/engagement/case-study-dr-alan-parker). Rwyf hefyd wedi ysgrifennu erthyglau lleyg ar gyfer y blog BSGCT (https://www.bsgct.org/author/alanparker/) ac adnoddau addysgol ASGCT. Rwy'n angerddol am wella rhagolygon gyrfa ar gyfer ymchwilwyr gyrfa gynnar (ECRs), ac fel aelod o fwrdd Cymdeithas Therapi Gene a Chelloedd Prydain, rwyf wedi sefydlu a rhedeg is-bwyllgor sy'n ymroddedig i ddatblygu Ymchwilwyr Gyrfa Gynnar, yn ogystal â diweddaru tudalen facebook BSGCT (www.facebook.com/BSGCT) a ffrwd Twitter (@_BSGCT) fel rhan o'm rôl ar is-bwyllgor cyfathrebu a hyrwyddo BSGCT.
Cyhoeddiad
2024
- Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131, pp. 1694-1706. (10.1038/s41416-024-02869-3)
- Bliss, C. M. et al. 2024. A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications. Molecular Therapy - Methods and Clinical Development 32(3), article number: 101308. (10.1016/j.omtm.2024.101308)
- Wallace, R., Bliss, C. M. and Parker, A. L. 2024. The immune system - A double-edged sword for adenovirus-based therapies. Viruses 16(6), article number: 973. (10.3390/v16060973)
- Gardner, J. et al. 2024. Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. npj Vaccines 9(1), article number: 99. (10.1038/s41541-024-00895-z)
2023
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Preston, H. E., Bayliss, R., Temperton, N., Neto, M. M., Brewer, J. and Parker, A. L. 2023. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation. iScience 26(9), article number: 107567. (10.1016/j.isci.2023.107567)
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15(16), article number: 4178. (10.3390/cancers15164178)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Othman, M. et al. 2023. Corrigendum to To clot or not to clot? Ad is the question?Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia [J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485]. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.01.022)
2022
- Swift, E. A., Pollard, S. M. and Parker, A. L. 2022. Engineering cancer selective virotherapies: are the pieces of the puzzle falling into place?. Human Gene Therapy 33(21-22) (10.1089/hum.2022.178)
- Cunliffe, T. G., Parker, A. L. and Jaramillo, A. 2022. Pseudotyping bacteriophage P2 tail fibers to extend the host range for biomedical applications. ACS Synthetic Biology 11(10), pp. 3207-3215. (10.1021/acssynbio.1c00629)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Toh, C., Wang, G. and Parker, A. L. 2022. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clinical Medicine 22(2), pp. 140-144. (10.7861/clinmed.2022-0006)
2021
- Tate, S. J., Van de Sande, L., Ceelen, W. P., Torkington, J. and Parker, A. L. 2021. The feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to administer oncolytic adenoviruses. Pharmaceutics 13(12), article number: 2043. (10.3390/pharmaceutics13122043)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Othman, M. et al. 2021. To clot or not to clot? Ad is the question - insights on mechanisms related to vaccine induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 19(11), pp. 2845-2856. (10.1111/jth.15485)
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
2020
- Wongthida, P. et al. 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22(12), pp. 1757-1770. (10.1093/neuonc/noaa126)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
- Mowbray, N. G. et al. 2020. Safe management of surgical smoke in the age of COVID-19. British Journal of Surgery 107(11), pp. 1406-1413. (10.1002/bjs.11679)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Crowther, M. D. et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21, pp. 178 - 185. (10.1038/s41590-019-0578-8)
2019
- Man, S., Foster, J., Carapuca, E., Davies, J. A., Parker, A., Sosabowski, J. and Hallden, G. 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9, article number: 12840. (10.1038/s41598-019-49150-9)
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
- Baker, A. T., Mundy, R., Davies, J., Rizkillah, P. T. and Parker, A. L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. [Online]. bioRxiv. (10.1101/580076) Available at: https://doi.org/10.1101/580076
- Baker, A. T. et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10, article number: 741. (10.1038/s41467-019-08599-y)
2018
- Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
- Baker, A., Aguirre-Hernández, C., Halldén, G. and Parker, A. 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6), article number: 201. (10.3390/cancers10060201)
- Hulin-Curtis, S., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D. and Parker, A. L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
- Man, Y. K. S. et al. 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17(2), pp. 575-587. (10.1158/1535-7163.MCT-17-0671)
- Uusi-Kerttula, H. and Parker, A. L. 2018. Precision virotherapies: Coming soon. Oncotarget 9(86) (10.18632/oncotarget.26280)
2017
- Yan, B., Wang, Z., Parker, A., Lai, Y., Thomas, J. P., Yue, L. and Monks, J. N. 2017. Superlensing microscope objective lens. Applied Optics 56(11), pp. 3142-3147. (10.1364/AO.56.003142)
2016
- Robertson, S., Alba, R., Duffy, M. R., Clarke, C., Parker, A. L., Nicklin, S. A. and Baker, A. H. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Hanna, L., Chester, J. D. and Parker, A. L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
- Uusi-Kerttula, H., Davies, J., Curtis, S., Chester, J. and Parker, A. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)
2015
- Uusi-Kerttula, H., Hulin-Curtis, S., Davies, J. A. and Parker, A. L. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923)
- Uusi-Kerttula, H., Davies, J. A., Coughlan, L., Chester, J. D., Parker, A. L. and Parker, A. L. 2015. Incorporation of avß6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites. Human Gene Therapy 26(10), pp. A93-A93., article number: P224. (10.1089/hum.2015.29008.abstracts)
- Uusi-Kerttula, H., Davies, J., Coughlan, L., Jones, R., Chester, J. D. and Parker, A. L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Baker, A., Chester, J. D. and Parker, A. L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
- Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A. and Baker, A. H. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019)
- Nivsarkar, M. S. et al. 2015. Evidence for contribution of CD4+CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery. Journal of Immunology Research 2015, article number: 397879. (10.1155/2015/397879)
2014
- Guinn, B., Braidwood, L., Parker, A., Peng, K. and Seymour, L. 2014. 8th international conference on oncolytic virus therapeutics. Human Gene Therapy 25(12), pp. 1062-1084. (10.1089/hum.2014.118)
- Dakin, R. S., Parker, A., Ma, J., Custers, J., Nicklin, S. A. and Baker, A. H. 2014. Efficient gene transfer to human vascular cells in vitro and ex vivo using adenovirus serotype 49. Cardiovascular Research 103(suppl), pp. S42. (10.1093/cvr/cvu082.170)
- Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L. and Baker, A. H. 2014. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy 25(4), pp. 385-394. (10.1089/hum.2014.016)
2013
- Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A. and Baker, A. H. 2013. Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. eds. Adenovirus., Vol. 1089. Methods in Molecular Biology Humana Press, pp. 45-59., (10.1007/978-1-62703-679-5_3)
- Parker, A. L., White, K. M., Lavery, C. A., Custers, J., Waddington, S. N. and Baker, A. H. 2013. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy 20(12), pp. 1158-1164. (10.1038/gt.2013.44)
- White, K. M. et al. 2013. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery 8(1), article number: 183. (10.1186/1749-8090-8-183)
- Kaur, H., Toukh, M., Corscadden, K., Parker, A. L. and Othman, M. 2013. Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction [Abstract]. Journal of Thrombosis and Haemostatis 11(S1), pp. 451-452. (10.1111/jth.12284)
- Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M. and Baker, A. H. 2013. Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170(1), pp. 132-140. (10.1016/j.jconrel.2013.05.007)
2012
- Coughlan, L. et al. 2012. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy 20(12), pp. 2268-2281. (10.1038/mt.2012.162)
- Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. 2012. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 7(2), pp. 271-288. (10.2217/nnm.11.186)
2011
- Coughlan, L., Uusi-Kerttula, H., Degg, B., Parker, A. L., Custers, J., Nicklin, S. A. and Baker, A. H. 2011. In vitro assessment of targeting peptide incorporation within the knob domain of human adenovirus type 48 fiber. Human Gene Therapy 22(10), pp. A128-A128.
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85(20), pp. 10914-10919. (10.1128/JVI.05382-11)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus:FX complexes [Abstract]. Human Gene Therapy 22(10), pp. A34-A34. (10.1089/hum.2011.2525)
- Kitahara, H. et al. 2011. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Molecular Cancer Research 9(6), pp. 688-701. (10.1158/1541-7786.MCR-10-0470)
2010
- Othman, M. et al. 2010. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 116(18), pp. 3645-3652. (10.1182/blood-2009-12-261131)
- Alba, R. et al. 2010. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15), pp. 2656-2664. (10.1182/blood-2009-12-260026)
- Bradshaw, A. C. et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathogens 6(10), article number: e1001142. (10.1371/journal.ppat.1001142)
- Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A. and Baker, A. H. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10), pp. 2290-2355. (10.3390/v2102290)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the factor X serine protease domain ablates heparan sulfate proteoglycan engagement by Ad5-FX complexes. Human Gene Therapy 21(9), pp. 1187-1187. (10.1089/hum.2010.804)
- Collins, L., Parker, A. L., Gehman, J. D., Eckley, L., Perugini, M. A., Separovic, F. and Fabre, J. W. 2010. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano 4(5), pp. 2856-2864. (10.1021/nn901414q)
- Parker, A. L., Alba, R., Barouch, D. H., Delles, C. and Baker, A. H. 2010. In vitro evaluation of hexon modifications on the capacity of Ad5 to evade neutralising antibodies. Human Gene Therapy 21(4), pp. 518-518. (10.1089/hum.2010.1225)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the FX serine protease domain ablates HSGP engagment by Ad5/FX complexes. Human Gene Therapy 21(4), pp. 512-513. (10.1089/hum.2010.1225)
- Alba, R. et al. 2010. Biodistribution and inflammatory profiles of hepatocyte-detargeted FX-binding ablated Ad5 vectors. Human Gene Therapy 21(4), pp. 498-499. (10.1089/hum.2010.1224)
2009
- Greig, J. A. et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular Therapy 17(10), pp. 1683-1691. (10.1038/mt.2009.152)
- Alba, R. et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114(5), pp. 965-971. (10.1182/blood-2009-03-208835)
- Greig, J. A. et al. 2009. Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors. Molecular Therapy 17, pp. S325-S325.
- Parker, A. L. et al. 2009. Genome wide and micro RNA profiling of murine livers following acute phase intravenous delivery of Ad5 reveals subsets of hepatocyte and kupffer cell regulated genes. Molecular Therapy 17, pp. S43-S44.
- Alba, R. et al. 2009. Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo. Molecular Therapy 17, pp. S6-S6.
- Parker, A. et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of Virology 83(1), pp. 479-483. (10.1128/JVI.01878-08)
2008
- Parker, A., Nicklin, S. A. and Baker, A. H. 2008. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics 10(5), pp. 439-448.
- Waddington, S. N. et al. 2008. A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy 19(4), pp. 409-409. (10.1089/hum.2008.1327)
- Parker, A. et al. 2008. An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy 19(4), pp. 407-407. (10.1089/hum.2008.1327)
- Greig, J. A. et al. 2008. Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy 19(4), pp. 398-398.
- Waddington, S. N. et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), pp. 397-409. (10.1016/j.cell.2008.01.016)
- Kubo, N., Akita, N., Shimizu, A., Kitahara, H., Parker, A. L. and Miyagawa, S. 2008. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting 16(5), pp. 396-404. (10.1080/10611860802088796)
2007
- Waddington, S. N., Parker, A. L., Havenga, M., Nicklin, S. A., Buckley, S. M. K., McVey, J. H. and Baker, A. H. 2007. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology 81(17), pp. 9568-9571. (10.1128/JVI.00663-07)
- Parker, A. L., Eckley, L., Singh, S., Preece, J. A., Collins, L. and Fabre, J. W. 2007. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1770(9), pp. 1331-1337. (10.1016/j.bbagen.2007.06.009)
- Parker, A. L. et al. 2007. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology 81(7), pp. 3627-3631. (10.1128/JVI.02786-06)
- Maruta, F. et al. 2007. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting 15(4), pp. 311-319. (10.1080/10611860701195510)
2006
- Akita, N. et al. 2006. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science 97(10), pp. 1075-1081. (10.1111/j.1349-7006.2006.00291.x)
- Parker, A. L. et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), pp. 2554-2561. (10.1182/blood-2006-04-008532)
- Parker, A. L. et al. 2006. Hepatic tropism of adenoviral type 5 vectors can be mediated by multiple coagulation factors. Molecular Therapy 13(S1), pp. S143-S143. (10.1016/j.ymthe.2006.08.436)
- Shimizu, A. et al. 2006. Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 71(1-2), pp. 136-145. (10.1159/000100479)
2005
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2005. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. Journal of Gene Medicine 7(12), pp. 1545-1554. (10.1002/jgm.809)
- Read, M. L., Spice, R., Parker, A. L., Mir, S. and Logan, A. 2005. 12th Annual Congress of the European Society of Gene Therapy. Expert Opinion on Biological Therapy 5(1), pp. 137-141. (10.1517/14712598.5.1.137)
- Parker, A. L., Fisher, K. D., Oupicky, D., Read, M. L., Nicklin, S. A., Baker, A. H. and Seymour, L. W. 2005. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting 13(1), pp. 39-51. (10.1080/10611860400020449)
2004
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2004. Free and (Lys)(16) containing fusogenic peptides for non-viral gene delivery to dividing and post mitotic cells. Journal of Gene Medicine 6(9), pp. S13-S13.
- Parker, A. L., Newman, C., Briggs, S., Seymour, L. and Sheridan, P. J. 2004. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Reviews in Molecular Medicine 5, pp. 1-15. (10.1017/S1462399403006562)
2003
- Maruta, F., Parker, A. L., Fisher, K. D., Murray, P. G., Kerr, D. J. and Seymour, L. W. 2003. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. Journal of Drug Targeting 11(1), pp. 53-59.
2002
- Parker, A. L. and Seymour, L. W. 2002. Targeting of polyelectrolyte RNA complexes to cell surface integrins as an efficient cytoplasmic transfection mechanism. Journal of Bioactive and Compatible Polymers 17(4), pp. 229-238. (10.1106/088391102027977)
- Maruta, F. et al. 2002. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy 9(6), pp. 543-552. (10.1038/sj.cgt.7700470)
- Parker, A. L., Oupicky, D., Dash, P. R. and Seymour, L. W. 2002. Methodologies for monitoring, nanoparticle formation by self-assembly of DNA with poly(L-lysine). Analytical Biochemistry 302(1), pp. 75-80. (10.1006/abio.2001.5507)
- Oupicky, D., Parker, A. L. and Seymour, L. W. 2002. Laterally stabilized complexes of DNA with linear reducible polycations: Strategy for triggered intracellular activation of DNA delivery vectors. Journal of the American Chemical Society 124(1), pp. 8-9. (10.1021/ja016440n)
2000
- Carlisle, R. C., Fisher, K. D., Parker, A. L. and Seymour, L. W. 2000. Systems for gene delivery based on combination of viral and non-viral vectors. Targeting of Drugs 323, pp. 117-125.
Articles
- Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131, pp. 1694-1706. (10.1038/s41416-024-02869-3)
- Bliss, C. M. et al. 2024. A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications. Molecular Therapy - Methods and Clinical Development 32(3), article number: 101308. (10.1016/j.omtm.2024.101308)
- Wallace, R., Bliss, C. M. and Parker, A. L. 2024. The immune system - A double-edged sword for adenovirus-based therapies. Viruses 16(6), article number: 973. (10.3390/v16060973)
- Gardner, J. et al. 2024. Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. npj Vaccines 9(1), article number: 99. (10.1038/s41541-024-00895-z)
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Preston, H. E., Bayliss, R., Temperton, N., Neto, M. M., Brewer, J. and Parker, A. L. 2023. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation. iScience 26(9), article number: 107567. (10.1016/j.isci.2023.107567)
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15(16), article number: 4178. (10.3390/cancers15164178)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Othman, M. et al. 2023. Corrigendum to To clot or not to clot? Ad is the question?Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia [J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485]. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.01.022)
- Swift, E. A., Pollard, S. M. and Parker, A. L. 2022. Engineering cancer selective virotherapies: are the pieces of the puzzle falling into place?. Human Gene Therapy 33(21-22) (10.1089/hum.2022.178)
- Cunliffe, T. G., Parker, A. L. and Jaramillo, A. 2022. Pseudotyping bacteriophage P2 tail fibers to extend the host range for biomedical applications. ACS Synthetic Biology 11(10), pp. 3207-3215. (10.1021/acssynbio.1c00629)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Toh, C., Wang, G. and Parker, A. L. 2022. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clinical Medicine 22(2), pp. 140-144. (10.7861/clinmed.2022-0006)
- Tate, S. J., Van de Sande, L., Ceelen, W. P., Torkington, J. and Parker, A. L. 2021. The feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to administer oncolytic adenoviruses. Pharmaceutics 13(12), article number: 2043. (10.3390/pharmaceutics13122043)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Othman, M. et al. 2021. To clot or not to clot? Ad is the question - insights on mechanisms related to vaccine induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 19(11), pp. 2845-2856. (10.1111/jth.15485)
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
- Wongthida, P. et al. 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22(12), pp. 1757-1770. (10.1093/neuonc/noaa126)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
- Mowbray, N. G. et al. 2020. Safe management of surgical smoke in the age of COVID-19. British Journal of Surgery 107(11), pp. 1406-1413. (10.1002/bjs.11679)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Crowther, M. D. et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21, pp. 178 - 185. (10.1038/s41590-019-0578-8)
- Man, S., Foster, J., Carapuca, E., Davies, J. A., Parker, A., Sosabowski, J. and Hallden, G. 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9, article number: 12840. (10.1038/s41598-019-49150-9)
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
- Baker, A. T. et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10, article number: 741. (10.1038/s41467-019-08599-y)
- Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
- Baker, A., Aguirre-Hernández, C., Halldén, G. and Parker, A. 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6), article number: 201. (10.3390/cancers10060201)
- Hulin-Curtis, S., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D. and Parker, A. L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
- Man, Y. K. S. et al. 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17(2), pp. 575-587. (10.1158/1535-7163.MCT-17-0671)
- Uusi-Kerttula, H. and Parker, A. L. 2018. Precision virotherapies: Coming soon. Oncotarget 9(86) (10.18632/oncotarget.26280)
- Yan, B., Wang, Z., Parker, A., Lai, Y., Thomas, J. P., Yue, L. and Monks, J. N. 2017. Superlensing microscope objective lens. Applied Optics 56(11), pp. 3142-3147. (10.1364/AO.56.003142)
- Robertson, S., Alba, R., Duffy, M. R., Clarke, C., Parker, A. L., Nicklin, S. A. and Baker, A. H. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Hanna, L., Chester, J. D. and Parker, A. L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
- Uusi-Kerttula, H., Davies, J., Curtis, S., Chester, J. and Parker, A. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)
- Uusi-Kerttula, H., Hulin-Curtis, S., Davies, J. A. and Parker, A. L. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923)
- Uusi-Kerttula, H., Davies, J. A., Coughlan, L., Chester, J. D., Parker, A. L. and Parker, A. L. 2015. Incorporation of avß6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites. Human Gene Therapy 26(10), pp. A93-A93., article number: P224. (10.1089/hum.2015.29008.abstracts)
- Uusi-Kerttula, H., Davies, J., Coughlan, L., Jones, R., Chester, J. D. and Parker, A. L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Baker, A., Chester, J. D. and Parker, A. L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
- Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A. and Baker, A. H. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019)
- Nivsarkar, M. S. et al. 2015. Evidence for contribution of CD4+CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery. Journal of Immunology Research 2015, article number: 397879. (10.1155/2015/397879)
- Guinn, B., Braidwood, L., Parker, A., Peng, K. and Seymour, L. 2014. 8th international conference on oncolytic virus therapeutics. Human Gene Therapy 25(12), pp. 1062-1084. (10.1089/hum.2014.118)
- Dakin, R. S., Parker, A., Ma, J., Custers, J., Nicklin, S. A. and Baker, A. H. 2014. Efficient gene transfer to human vascular cells in vitro and ex vivo using adenovirus serotype 49. Cardiovascular Research 103(suppl), pp. S42. (10.1093/cvr/cvu082.170)
- Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L. and Baker, A. H. 2014. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy 25(4), pp. 385-394. (10.1089/hum.2014.016)
- Parker, A. L., White, K. M., Lavery, C. A., Custers, J., Waddington, S. N. and Baker, A. H. 2013. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy 20(12), pp. 1158-1164. (10.1038/gt.2013.44)
- White, K. M. et al. 2013. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery 8(1), article number: 183. (10.1186/1749-8090-8-183)
- Kaur, H., Toukh, M., Corscadden, K., Parker, A. L. and Othman, M. 2013. Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction [Abstract]. Journal of Thrombosis and Haemostatis 11(S1), pp. 451-452. (10.1111/jth.12284)
- Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M. and Baker, A. H. 2013. Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170(1), pp. 132-140. (10.1016/j.jconrel.2013.05.007)
- Coughlan, L. et al. 2012. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy 20(12), pp. 2268-2281. (10.1038/mt.2012.162)
- Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. 2012. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 7(2), pp. 271-288. (10.2217/nnm.11.186)
- Coughlan, L., Uusi-Kerttula, H., Degg, B., Parker, A. L., Custers, J., Nicklin, S. A. and Baker, A. H. 2011. In vitro assessment of targeting peptide incorporation within the knob domain of human adenovirus type 48 fiber. Human Gene Therapy 22(10), pp. A128-A128.
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85(20), pp. 10914-10919. (10.1128/JVI.05382-11)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus:FX complexes [Abstract]. Human Gene Therapy 22(10), pp. A34-A34. (10.1089/hum.2011.2525)
- Kitahara, H. et al. 2011. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Molecular Cancer Research 9(6), pp. 688-701. (10.1158/1541-7786.MCR-10-0470)
- Othman, M. et al. 2010. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 116(18), pp. 3645-3652. (10.1182/blood-2009-12-261131)
- Alba, R. et al. 2010. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15), pp. 2656-2664. (10.1182/blood-2009-12-260026)
- Bradshaw, A. C. et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathogens 6(10), article number: e1001142. (10.1371/journal.ppat.1001142)
- Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A. and Baker, A. H. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10), pp. 2290-2355. (10.3390/v2102290)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the factor X serine protease domain ablates heparan sulfate proteoglycan engagement by Ad5-FX complexes. Human Gene Therapy 21(9), pp. 1187-1187. (10.1089/hum.2010.804)
- Collins, L., Parker, A. L., Gehman, J. D., Eckley, L., Perugini, M. A., Separovic, F. and Fabre, J. W. 2010. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano 4(5), pp. 2856-2864. (10.1021/nn901414q)
- Parker, A. L., Alba, R., Barouch, D. H., Delles, C. and Baker, A. H. 2010. In vitro evaluation of hexon modifications on the capacity of Ad5 to evade neutralising antibodies. Human Gene Therapy 21(4), pp. 518-518. (10.1089/hum.2010.1225)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the FX serine protease domain ablates HSGP engagment by Ad5/FX complexes. Human Gene Therapy 21(4), pp. 512-513. (10.1089/hum.2010.1225)
- Alba, R. et al. 2010. Biodistribution and inflammatory profiles of hepatocyte-detargeted FX-binding ablated Ad5 vectors. Human Gene Therapy 21(4), pp. 498-499. (10.1089/hum.2010.1224)
- Greig, J. A. et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular Therapy 17(10), pp. 1683-1691. (10.1038/mt.2009.152)
- Alba, R. et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114(5), pp. 965-971. (10.1182/blood-2009-03-208835)
- Greig, J. A. et al. 2009. Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors. Molecular Therapy 17, pp. S325-S325.
- Parker, A. L. et al. 2009. Genome wide and micro RNA profiling of murine livers following acute phase intravenous delivery of Ad5 reveals subsets of hepatocyte and kupffer cell regulated genes. Molecular Therapy 17, pp. S43-S44.
- Alba, R. et al. 2009. Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo. Molecular Therapy 17, pp. S6-S6.
- Parker, A. et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of Virology 83(1), pp. 479-483. (10.1128/JVI.01878-08)
- Parker, A., Nicklin, S. A. and Baker, A. H. 2008. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics 10(5), pp. 439-448.
- Waddington, S. N. et al. 2008. A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy 19(4), pp. 409-409. (10.1089/hum.2008.1327)
- Parker, A. et al. 2008. An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy 19(4), pp. 407-407. (10.1089/hum.2008.1327)
- Greig, J. A. et al. 2008. Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy 19(4), pp. 398-398.
- Waddington, S. N. et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), pp. 397-409. (10.1016/j.cell.2008.01.016)
- Kubo, N., Akita, N., Shimizu, A., Kitahara, H., Parker, A. L. and Miyagawa, S. 2008. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting 16(5), pp. 396-404. (10.1080/10611860802088796)
- Waddington, S. N., Parker, A. L., Havenga, M., Nicklin, S. A., Buckley, S. M. K., McVey, J. H. and Baker, A. H. 2007. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology 81(17), pp. 9568-9571. (10.1128/JVI.00663-07)
- Parker, A. L., Eckley, L., Singh, S., Preece, J. A., Collins, L. and Fabre, J. W. 2007. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1770(9), pp. 1331-1337. (10.1016/j.bbagen.2007.06.009)
- Parker, A. L. et al. 2007. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology 81(7), pp. 3627-3631. (10.1128/JVI.02786-06)
- Maruta, F. et al. 2007. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting 15(4), pp. 311-319. (10.1080/10611860701195510)
- Akita, N. et al. 2006. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science 97(10), pp. 1075-1081. (10.1111/j.1349-7006.2006.00291.x)
- Parker, A. L. et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), pp. 2554-2561. (10.1182/blood-2006-04-008532)
- Parker, A. L. et al. 2006. Hepatic tropism of adenoviral type 5 vectors can be mediated by multiple coagulation factors. Molecular Therapy 13(S1), pp. S143-S143. (10.1016/j.ymthe.2006.08.436)
- Shimizu, A. et al. 2006. Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 71(1-2), pp. 136-145. (10.1159/000100479)
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2005. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. Journal of Gene Medicine 7(12), pp. 1545-1554. (10.1002/jgm.809)
- Read, M. L., Spice, R., Parker, A. L., Mir, S. and Logan, A. 2005. 12th Annual Congress of the European Society of Gene Therapy. Expert Opinion on Biological Therapy 5(1), pp. 137-141. (10.1517/14712598.5.1.137)
- Parker, A. L., Fisher, K. D., Oupicky, D., Read, M. L., Nicklin, S. A., Baker, A. H. and Seymour, L. W. 2005. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting 13(1), pp. 39-51. (10.1080/10611860400020449)
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2004. Free and (Lys)(16) containing fusogenic peptides for non-viral gene delivery to dividing and post mitotic cells. Journal of Gene Medicine 6(9), pp. S13-S13.
- Parker, A. L., Newman, C., Briggs, S., Seymour, L. and Sheridan, P. J. 2004. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Reviews in Molecular Medicine 5, pp. 1-15. (10.1017/S1462399403006562)
- Maruta, F., Parker, A. L., Fisher, K. D., Murray, P. G., Kerr, D. J. and Seymour, L. W. 2003. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. Journal of Drug Targeting 11(1), pp. 53-59.
- Parker, A. L. and Seymour, L. W. 2002. Targeting of polyelectrolyte RNA complexes to cell surface integrins as an efficient cytoplasmic transfection mechanism. Journal of Bioactive and Compatible Polymers 17(4), pp. 229-238. (10.1106/088391102027977)
- Maruta, F. et al. 2002. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy 9(6), pp. 543-552. (10.1038/sj.cgt.7700470)
- Parker, A. L., Oupicky, D., Dash, P. R. and Seymour, L. W. 2002. Methodologies for monitoring, nanoparticle formation by self-assembly of DNA with poly(L-lysine). Analytical Biochemistry 302(1), pp. 75-80. (10.1006/abio.2001.5507)
- Oupicky, D., Parker, A. L. and Seymour, L. W. 2002. Laterally stabilized complexes of DNA with linear reducible polycations: Strategy for triggered intracellular activation of DNA delivery vectors. Journal of the American Chemical Society 124(1), pp. 8-9. (10.1021/ja016440n)
- Carlisle, R. C., Fisher, K. D., Parker, A. L. and Seymour, L. W. 2000. Systems for gene delivery based on combination of viral and non-viral vectors. Targeting of Drugs 323, pp. 117-125.
Book sections
- Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A. and Baker, A. H. 2013. Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. eds. Adenovirus., Vol. 1089. Methods in Molecular Biology Humana Press, pp. 45-59., (10.1007/978-1-62703-679-5_3)
Websites
- Baker, A. T., Mundy, R., Davies, J., Rizkillah, P. T. and Parker, A. L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. [Online]. bioRxiv. (10.1101/580076) Available at: https://doi.org/10.1101/580076
Ymchwil
Firoleg Adenofirws
Mae ymchwil o fewn labordy Parker yn canolbwyntio ar ddatblygu fectorau adenofirysol oncolytig pwrpasol ar gyfer cymwysiadau canser trosiadol. Er mwyn cyflawni hyn, rydym yn datblygu firotherapïau dethol tiwmor sy'n heintio celloedd canser yn ddetholus, gan adael celloedd arferol heb eu heintio. Er mwyn cyflawni hyn, rydym yn cymryd dau ddull. Ein dull cyntaf yw dull "o'r gwaelod i fyny" sy'n cynnwys defnyddio Ad5, firws wedi'i ddisgrifio'n dda, wedi'i ddeall yn dda ac sy'n cael ei astudio'n dda yn glinigol. Er ei fod yn ddiogel, mae gan Ad5 nifer o nodweddion sy'n cyfyngu ar effeithiolrwydd fel firotherapi dethol tiwmor.
Yn gyntaf, mae'r derbynnydd Ad5 sylfaenol, hCAR (coxsackie dynol a derbynnydd adenovirus) yn cael ei fynegi'n hollbresennol ar gelloedd coch y gwaed ac ym mhob meinwe, sydd wedi'u lleoli ar gyffyrdd tynn, ond yn cael ei isreoleiddio yn aml neu hyd yn oed yn absennol mewn canserau datblygedig, ac felly mae'n cynrychioli targed gwael ar gyfer strategaethau targedu tiwmorau.
Yn ail, gall y defnydd o gelloedd imiwnedd, wedi'i gyfryngu gan y rhyngweithio rhwng integryn αvβ3 / 5 a'r protein sylfaen penton Ad5 hyrwyddo dogn sylweddol sy'n cyfyngu ar wenwyndra.
Yn olaf, mae cyflenwi intrafasgwlaidd Ad5, rhagofyniad ar gyfer therapi clefyd metastatig, yn cael ei gyfaddawdu ar gyfer Ad5 oherwydd y rhyngweithio affinedd uchel â'r ffactor ceulo gwaed, FX, sy'n pontio'r firws: cymhleth FX i HSPGs ac mae'n gyfrifol am y lefelau sylweddol o faint o bobl sy'n defnyddio hepatig o virotherapies seiliedig ar Ad5 (wedi'u goruchwylio yn ffigur 1). Er mwyn targedu'r fector basal mireinio i gelloedd tiwmor, rydym yn modiwleiddio'r fector ymhellach i ymgorffori ligands peptid sy'n rhwymo i farcwyr tiwmor penodol, fel integryn αvβ6 (ffigur 2).
Mae ein hail ddull yn cynrychioli dull "o'r brig i lawr." Mae Ad5 yn cynrychioli un o deulu amrywiol o firysau, ar hyn o bryd yn rhifo 57 seroteip, sy'n rhychwantu 7 rhywogaeth (A-G). Mae gan lawer o'r firysau hyn trofannau unigryw, wedi'u cyfryngu trwy ryngweithio â derbynyddion heb eu dogfennu eto. At hynny, anaml y mae llawer o'r seroteipiau Ad amgen hyn yn ynysig ac felly mae ganddynt lefelau cyfyngedig iawn o imiwnedd sy'n bodoli eisoes yn y boblogaeth gyffredinol, sy'n debygol o fod yn fanteisiol wrth eu defnyddio'n glinigol.
Rydym yn archwilio amrywiaeth naturiol trobwynt Ad trwy geisio datblygu fectorau sy'n seiliedig ar Hysbysebion prin ynysig o rywogaethau B a D. Rydym yn ymchwilio i ryngweithiadau derbynyddion posibl ar y lefel foleciwlaidd trwy ddatrys strwythur y trobwynt mawr sy'n pennu epitopau mewn cydraniad uwch-uchel gan ddiffreithiant pelydr-X, ac yn fiolegol trwy ddefnyddio technegau moleciwlaidd soffistigedig i gynhyrchu fectorau firaol chimerig. Cafodd ein papur diweddar ar strwythur a swyddogaeth rhywogaethau D (y gellir ei gyrchu yma http://dx.doi.org/10.1038/s41467-019-08599-y) ei gynnwys mewn sawl siop newyddion yn ddiweddar ac fe'i trafodwyd mewn datganiad i'r wasg (http://www.cardiff.ac.uk/news/view/1442255-seeing-the-unseeable)
Cafodd ein hymchwil ar virotherapies wedi'i dargedu sylw ar-lein yn ddiweddar ar wefan newyddion y BBC:
http://www.bbc.co.uk/news/uk-wales-south-east-wales-40305580
https://www.bbc.co.uk/news/uk-wales-44237820
Yn ogystal ag ymddangos ar BBC Cymru heddiw:
Yn y ddolen isod, rydym yn disgrifio ein prosiect CRUK a ariannwyd yn ddiweddar, gan ddatblygu firotherapïau seiliedig ar adenofiraol sydd wedi'u "hyfforddi" i frwydro canser yr ofari:
https://www.youtube.com/watch?v=DDQPpZHZbo0&t=12s
Amlygwyd ein hymchwil hefyd mewn rhifyn diweddar (Hydref 2017) o Advances Wales (tud12)
Roedd ein hymchwil ar y cyd â Gunnel Hallden (Sefydliad Canser Bart) ar firotherapïau wedi'u targedu ar gyfer canser y pancreas yn destun sylw sylweddol i'r wasg - ac edrychwn ymlaen at ehangu'r cydweithrediad trosiadol cyffrous hwn ymhellach!
http://www.cardiff.ac.uk/news/view/1083809-inhibiting-the-growth-of-pancreatic-cancer
Addysgu
Rwy'n perfformio ystod eang o ymrwymiadau addysgu ar gyfer y Brifysgol, yn ogystal ag addysgu ac ymgysylltu sylweddol i'r gymuned ehangach. Yn benodol, ym mhrifysgol Caerdydd rwy'n:
- Dylunio a pherfformio Cydrannau a Ddewisir gan Fyfyrwyr (SSCs) ar gyfer myfyrwyr meddygol israddedig.
- Rhedeg tiwtorialau ar gyfer myfyrwyr meddygol ar sut i adolygu papurau gwyddonol yn feirniadol.
- Perfformio tiwtorialau firoleg a darlithoedd fel rhan o'r rhaglen israddedig.
- Gweithredu fel tiwtor personol i fyfyrwyr meddygol israddedig.
- Gweithredu fel arfarnwr panel PhD ar gyfer >10 o fyfyrwyr PhD o fewn Is-adrannau Canser a Geneteg ac Is-adran Haint ac Imiwnedd.
- Goruchwylio prosiectau ymchwil israddedig.
- Goruchwylio prosiectau myfyrwyr ERASMUS.
- Goruchwylio prosiectau myfyrwyr PTY.
- Gweithredu fel aseswr ar gyfer prosiectau ymchwil israddedig.
- Gweithredu fel mentor personol i 7 myfyriwr PhD ar draws Is-adrannau Canser a Geneteg a Heintiau ac Imiwnedd.
- Gweithredu'n rheolaidd fel aelod panel PhD ar gyfer vivas myfyriwr PhD (ar hyn o bryd 6 gwaith fel arholwr allanol, 3 gwaith fel arholwr mewnol a 13 gwaith fel cadeirydd viva).
Bywgraffiad
Dechreuodd fy niddordeb mewn therapi genynnau a chelloedd wrth astudio ar gyfer fy ngradd israddedig mewn Geneteg (Prifysgol Sheffield), a ysbrydolodd fi i ddilyn PhD yn y maes hwn. Perfformiwyd fy PhD dan oruchwyliaeth yr Athro Len Seymour (sydd bellach ym Mhrifysgol Rhydychen) yn Sefydliad Astudiaethau Canser CRUK ym Mhrifysgol Birmingham, a cwblheais fy thesis o'r enw "Datblygu Systemau Cyflenwi Gene wedi'u Targedu Peptid" yn 2003.
Fy swydd ôl-ddoethurol gyntaf oedd dan oruchwyliaeth yr Athro John Fabre, lle datblygais systemau peptid bioymateb newydd ar gyfer cyflwyno genynnau lleol (2003-2005) a chyhoeddais sawl erthygl o'r swydd hon. Tra yn y sefyllfa hon datblygais hefyd a phatentwyd ffurf amlbwrpas, drefnus iawn o nanoronyn ar gyfer dosbarthu cyffuriau cyflym, targedadwy neu mRNA / miRNAs i sytoplasm celloedd targed (Collins L, Parker AL et al, ACS Nano, 2010).
Fy awydd i weithio ar fectorau firaol ar gyfer cymwysiadau therapi genynnau a chelloedd gan arwain at adleoli i Brifysgol Glasgow o 2005-2013, lle gwnes gyfraniadau pwysig at sut mae fectorau Adenoviral (Ad) yn rhyngweithio â chelloedd a phroteinau lletyol, a sut mae'r rhyngweithiadau hyn yn pennu troffedd firaol a gwenwyndra. Yn 2007 dyfarnwyd Cymrodoriaeth Personol RSE nodedig i mi gynhyrchu fectorau Ad mwy diogel a mwy effeithiol ar gyfer cymwysiadau in vivo. Yn 2010-2013 roeddwn i'n Uwch Wyddonydd a ariannwyd gan BHF. Yn ystod y cyfnod hwn, cyhoeddais nifer o erthyglau effaith uchel (pathogenau Cell, Gwaed, PLoS, Therapi Moleciwlaidd, Journal of Virology), a phatent defnyddio Seroteip newydd ar gyfer cymwysiadau therapi genynnau.
Yn 2013 arweiniodd fy awydd i gymhwyso fy ngwybodaeth adenoviral yn y lleoliad canser at fy adleoli i Brifysgol Caerdydd fel Darlithydd ac arweinydd grŵp. Yn 2014 cefais fy nyrchafu yn Uwch Ddarlithydd, y Darllenydd yn 2018, ac i Athro Therapïau Trosiadol yn 2020. Ers 2020 rwy'n arwain rhaglen therapiwtig wedi'i thargedu yng Nghanolfan Ymchwil Canser Cymru (https://www.walescancerresearchcentre.org/wcrc/) a ariennir gan HCRW. Rwyf wedi bod yn aelod etholedig o fwrdd Cymdeithas Therapi Gene a Chelloedd Prydain (https://www.bsgct.org/) ers 2014, ac rwyf wedi bod yn Drysorydd i'r gymdeithas ers 2020.
Rwy'n ffodus i arwain grŵp o unigolion ymroddedig sy'n ehangu ac yn hynod dalentog yn yr Is-adran Canser a Geneteg, lle rydym yn symud ymlaen y genhedlaeth nesaf at y clinig, wedi'i ategu gan gefnogaeth ffanstatig gan ein prif gyllidwyr, Cancer Research UK, Cance Research Wales, Gofal Canser Tenovus, Ymchwil Iechyd a Gofal Cymru a KESS 2.
Anrhydeddau a dyfarniadau
- Arweinydd Rhaglen ar gyfer Canolfan Ymchwil Canser Cymru: Therapiwteg wedi'i Dargedu (2020-2025)
- Trysorydd Cymdeithas Therapi Gene a Chelloedd Prydain (2020-2024)
- Trefnydd a chadeirydd y pwyllgor trefnu lleol ar gyfer 14eg Cyfarfod Blynyddol Cymdeithas Therapi Genynnau a Chelloedd Prydain (Caerdydd, Ebrill 2017)
- Cyfranogwr yn Grwsibl Cymru 2015.
- Etholwyd yn aelod o'r Bwrdd BSGCT (2014-2017, a ail-etholwyd yn 2017-2020), lle sefydlais a chadeirydd yr is-bwyllgor Datblygu a Chydweithio Gyrfa Cynnar ac rwy'n chwarae rhan weithredol fel aelod o'r is-bwyllgor cyfathrebu a hyrwyddo.
- Dyfarnwyd "Gwobr Rhagoriaeth mewn Ymchwil" 2006 gan Gymdeithas Therapi Gene a Cell America am fy ymchwil ar fectorau adenoviral a'u rhyngweithio â ffactorau ceulo.
- Yn ail yng nghategori NEXXUS "Ymchwilydd Biofeddygol Ifanc y Flwyddyn" 2007.
- Dyfarnwyd Cymrodoriaeth Cymdeithas Frenhinol Caeredin hynod gystadleuol yn y Gwyddorau Biofeddygol (2007-2010) i ddatblygu fectorau adenoviral heb ryngweithiadau ffactor geulo ar gyfer cymwysiadau in vivo.
- Gwobr Grant Teithio, Cymdeithas Therapi Gene a Chell America, 2006 a 2008.
- Aelod o'r Pwyllgor Grant - NC3Rs.
- Adolygydd grant ar gyfer MRC, Ymchwil Canser y Byd, Asiantaeth Ymchwil Genedlaethol Ffrainc, Fonds de recherche du Québec – Santé a Lles Menywod.
- Adolygydd llawysgrifau rheolaidd ar gyfer amrywiaeth o gyfnodolion effaith uchel.
- Cadeirydd sesiwn BSGCT 2012, 2014, 2016, 2017.
- Bwrdd golygyddol – Cylchgrawn cemotherapi.
- adolygydd haniaethol ar gyfer BSGCT, ASGCT a ESGCT.
Aelodaethau proffesiynol
- Aelod sefydlol Cymdeithas Therapi Gene a Chelloedd Prydain (2003-), aelod etholedig o'r bwrdd (2014-17), cadeirydd yr is-bwyllgor Datblygu a Chydweithio Gyrfa Cynnar, is-gadeirydd yr is-bwyllgor Aelodaeth ac Ymwybyddiaeth, ac aelod o is-bwyllgor Ymgysylltu â'r Cyhoedd.
- Aelod Cyswllt o Gymdeithas Therapi Gene a Chelloedd America (2003-), ac rwyf wedi ysgrifennu safbwyntiau cyfeiriadedd cleifion lleyg ar gyfer gwefan ASGCT ar ddatblygiadau diweddar ym maes therapi genynnau.
- Aelod o'r Gymdeithas Microbioleg (Cymdeithas Microbioleg Gyffredinol gynt)
- Rwy'n llysgennad STEM cofrestredig, ac felly rwy'n neilltuo fy amser fy hun i weithgareddau allgymorth mewn ysgolion lleol sy'n ceisio ysbrydoli cenedlaethau newydd o blant i mewn i wyddoniaeth. Rwyf hefyd yn perfformio gweithgareddau ymgysylltu sylweddol gyda grwpiau cymorth cleifion lleol ac elusennau. Mae fy ngweithgareddau ymgysylltu yn ddigon sylweddol i fod wedi bod yn sail i adroddiad achos gan Ysgol Meddygaeth Prifysgol Caerdydd.
Safleoedd academaidd blaenorol
Mehefin 2021 - Yn bresennol: Pennaeth Canserau Solid, Is-adran Canser a Geneteg, Ysgol Meddygaeth Prifysgol Caerdydd.
Awst 2020 - Yn bresennol: Athro Therapïau Trosiadol, Ysgol Meddygaeth Prifysgol Caerdydd.
Awst 2018 - Gorffennaf 2020: Darllenydd mewn Therapïau Trosiadol, Ysgol Meddygaeth Prifysgol Caerdydd.
Awst 2014 - Gorffennaf 2018: Uwch Ddarlithydd mewn Oncoleg Drosiadol, Ysgol Meddygaeth Prifysgol Caerdydd.
Chwefror 2013 - Gorffennaf 2014: Darlithydd mewn Oncoleg Drosiadol, Ysgol Meddygaeth Prifysgol Caerdydd.
Hydref 2010 – Ionawr 2013: BHF Uwch Wyddonydd, BHF Glasgow Cardiovascular Research Centre (GCRC), Prifysgol Glasgow.
Hydref 2007 – Medi 2010: Cymrawd Cymdeithas Frenhinol Caeredin yn y Gwyddorau Biofeddygol, BHF Glasgow Cardiovascular Research Centre (GCRC), Prifysgol Glasgow.
Medi 2005 – Medi 2007: Canolfan Ymchwil Cyswllt BHF Glasgow Cardiovascular Research Centre (GCRC), Prifysgol Glasgow.
Awst 2003 – Awst 2005: Cydymaith Ymchwil, King's College Llundain (Adran y Gwyddorau Clinigol).
Pwyllgorau ac adolygu
Pwyllgorau mewnol:
- 2017 - presennol: aelod o bwyllgor DCG EDI
- 2015 – presennol: Trefnydd cyfres seminarau ar gyfer y Sefydliad Canser a Geneteg, Prifysgol Caerdydd, y DU.
- 2014 – presennol: Aelod o bwyllgor GMBA , Coleg y Gwyddorau Biofeddygol a Bywyd, Prifysgol Caerdydd, y DU.
- 2013 – presennol: Panel Adolygu Myfyrwyr, Is-adran Canser a Geneteg ac Is-adran Heintiau ac Imiwnedd, Prifysgol Caerdydd, y DU.
- 2007 – 2013: Aelod o bwyllgor GM, Sefydliad y Gwyddorau Cardiofasgwlaidd a Meddygol, Prifysgol Glasgow, UK
- 2007 – 2013 Swyddog Diogelwch Biolegol, Sefydliad y Gwyddorau Cardiofasgwlaidd a Meddygol, Prifysgol Glasgow, UK
Pwyllgorau Allanol
- Grŵp goruchwyliaeth genedlaethol - therapïau celloedd a genynnau yng Nghymru
- 2015 - yn bresennol: NC3Rs CrackIT adolygiad aelod panel
- adolygydd pwyllgor haniaethol ar gyfer American Society for Gene and Cell Therapy
- adolygydd pwyllgor haniaethol ar gyfer British Society for Gene and Cell Therapy
- adolygydd pwyllgor haniaethol ar gyfer Cymdeithas Ewropeaidd ar gyfer Therapi Gene a Chelloedd
- Adolygydd grant ar gyfer MRC, Ymchwil Canser y Byd, Asiantaeth Ymchwil Genedlaethol Ffrainc, Fonds de recherche du Québec – Santé a Lles Menywod
Meysydd goruchwyliaeth
Mae fy nhîm yn gymysgedd ffyniannus o gymrodyr, staff ôl-ddoethurol, myfyrwyr ymchwil a staff technegol. Maen nhw'n bleser gweithio gyda nhw.
Rydym yn falch iawn o fod yn gweithio gyda Dr Carly Bliss ers mis Mehefin 2020, a ymunodd â ni fel cymrawd ymchwil annibynnol (a ariennir gan gyllid Cymrodoriaeth Ymchwil Wellcome ISSF) ac ers hynny mae wedi cael ei ddyrchafu'n ddarlithydd, gan ddatblygu ein llwyfannau firaol fel brechlynnau ar gyfer canser ac ar gyfer clefydau heintus.
Ar hyn o bryd mae'r ymchwilwyr ôl-ddoethurol canlynol yn cael eu cyflogi yn fy ngrŵp
- Dr Rebecca Bayliss
- Dr Luned Badder
- Dr Mahulena Marsukova
- Dr Charley Lovatt
- Dr Alicia Teijeira Crespo
- Dr Rebecca Wallace
- Dr Emily Bates
Mae'r grŵp yn cael ei gefnogi gan ddau aelod technegol gwych o staff
- Mrs Zulfa Yoosuf Aly
- Dr Andy Robnson.
O fewn y grŵp, rwy'n goruchwylio myfyrwyr PhD/MD/Phil canlynol ar hyn o bryd.
- Emma Swift (a ariennir gan Cancer Research UK, dan oruchwyliaeth Dr Pierre Rizkallah a Dr James Davies).
- Rosie Mundy (ariannwyd gan GW4, dan oruchwyliaeth Dr David Matthews (Bryste), Dr Carly Bliss a Dr Pierre Rizkallah).
- Adam Naskretski (a ariennir yn rhannol gan gronfa Gyncolegol De-ddwyrain Cymru, dan oruchwyliaeth Toby Phesse, Sadie Jones a Rebecca Bayliss).
- Lucy Williams (wedi'i ariannu gan MRC GW4 DTP)
- Mariana Verela Pereira (a ariennir gan Sefydliad Mosawi).
Ar hyn o bryd rwy'n goruchwylio'r prosiectau ymchwil israddedig canlynol
- James Thetford (Myfyriwr PTY, Prifysgol Caerdydd): 5T4 fel derbynnydd mynediad adenoviral
- Caitlin Dop (myfyrwraig PTY, Prifysgol Caerdydd): Dylunio brechlynnau coronafeirws cyffredinol
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD/MD yn y meysydd canlynol:
- Firotherapies canser
- Cyflwyno cyffuriau
- Datblygiad brechlyn
- Therapi Gene
- Firoleg (gyda phwyslais arbennig ar fectorau adenofiraol)
- Firws: rhyngweithiadau cynnal
- Imiwnotherapïau
Therapïau cyfunol sy'n cynnwys firotherapïau (gan gynnwys radiotherapi, chemotherapiau, imiwnotherapi, therapïau epigenetig)
Goruchwyliaeth gyfredol
Jaya Vangara
Myfyriwr ymchwil
Ymgysylltu
I perform a significant amount of engagement activity on behalf of both School and for the British Society for Gene and Cell Therapy. I am a registered STEMNet ambassador, and regularly attend a variety of events including school outreach events to public and patient engagement events and science festivals, as well as writing lay blog articles on gene and cell therapy (see https://www.bsgct.org/author/alanparker/). My commitment to engagement has resulted in my featuring in a School of Medicine "Public Engagement and Involvement in Research" case study which can be accessed here http://alanp14.tripod.com/Papers/_parkercasestudy.pdf
Contact Details
ParkerAL@caerdydd.ac.uk
+44 29225 10231
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29225 10231
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- Firoleg
- oncoleg fanwl
- Therapïau Uwch
- therapi genynnau
- Virotherapy
